Compare Stocks

→ The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTIC CTI BioPharma	$9.09	$9.06	$4.01 ▼ $9.10	$1.20B	0.83	4.50 million shs	N/A
DMAC DiaMedica Therapeutics	$2.58 +2.0%	$2.79	$1.53 ▼ $4.75	$97.94M	1.69	40,511 shs	7,764 shs
MRKR Marker Therapeutics	$4.36	$4.28	$0.76 ▼ $9.68	$38.80M	1.5	20,321 shs	12,556 shs
STSA Satsuma Pharmaceuticals	$1.10 -0.9%	$1.08	$0.59 ▼ $8.08	$36.47M	0.1	701,788 shs	1.83 million shs

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTIC CTI BioPharma	0.00%	0.00%	0.00%	0.00%	+84.01%
DMAC DiaMedica Therapeutics	+3.27%	+1.61%	-6.99%	-5.24%	+60.13%
MRKR Marker Therapeutics	-0.80%	+6.46%	+0.81%	-0.57%	+436.83%
STSA Satsuma Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+4.75%

The Next Step of Their Control Is Here … (Ad)

Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.

4 simple steps to protect your privacy and money before it’s too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTIC CTI BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	1.9861 of 5 stars	3.5	4.0	0.0	0.0	3.2	0.0	0.0
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTIC CTI BioPharma	2.00	Hold	N/A	N/A
DMAC DiaMedica Therapeutics	3.00	Buy	$7.00	171.32% Upside
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest STSA, DMAC, CTIC, and MRKR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/24/2024	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
3/21/2024	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
3/21/2024	DMAC DiaMedica Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$7.00 ➝ $6.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTIC CTI BioPharma	$53M	22.62	N/A	N/A	($0.14) per share	-64.93
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.35 per share	N/A
MRKR Marker Therapeutics	$3.31M	11.72	N/A	N/A	$1.58 per share	2.76
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTIC CTI BioPharma	-$92.99M	-$0.58	N/A	26.74	N/A	-91.38%	N/A	-55.82%	N/A
DMAC DiaMedica Therapeutics	-$19.38M	-$0.62	N/A	∞	N/A	N/A	-40.07%	-37.90%	5/20/2024 (Estimated)
MRKR Marker Therapeutics	-$8.24M	N/A	0.00	∞	N/A	-142.62%	-39.89%	-25.45%	5/21/2024 (Estimated)
STSA Satsuma Pharmaceuticals	-$70.06M	-$2.01	N/A	N/A	N/A	N/A	-115.24%	-102.26%	N/A

Latest STSA, DMAC, CTIC, and MRKR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/20/2024	N/A	DMAC DiaMedica Therapeutics	-$0.14	-$0.14	N/A	-$0.14	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTIC CTI BioPharma	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTIC CTI BioPharma	N/A	1.27	1.26
DMAC DiaMedica Therapeutics	N/A	19.27	19.27
MRKR Marker Therapeutics	N/A	5.57	5.57
STSA Satsuma Pharmaceuticals	N/A	7.44	7.44

Ownership

Institutional Ownership

Company	Institutional Ownership
CTIC CTI BioPharma	91.45%
DMAC DiaMedica Therapeutics	10.12%
MRKR Marker Therapeutics	22.39%
STSA Satsuma Pharmaceuticals	93.26%

Insider Ownership

Company	Insider Ownership
CTIC CTI BioPharma	7.61%
DMAC DiaMedica Therapeutics	7.20%
MRKR Marker Therapeutics	24.10%
STSA Satsuma Pharmaceuticals	31.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CTIC CTI BioPharma	127	131.88 million	121.84 million	Optionable
DMAC DiaMedica Therapeutics	18	37.96 million	35.23 million	Optionable
MRKR Marker Therapeutics	8	8.90 million	6.76 million	Not Optionable
STSA Satsuma Pharmaceuticals	21	33.15 million	22.81 million	Not Optionable

STSA, DMAC, CTIC, and MRKR Headlines

Source	Headline
	With manufacturing-related rejection, FDA turns its nose up at Satsuma's migraine nasal spray fiercepharma.com - January 18 at 8:54 PM
	Satsuma City High School usnews.com - August 30 at 5:25 PM
	Japanese pharma acquires its crash-strapped Durham spin-out bizjournals.com - June 9 at 3:18 PM
	Japanese pharma acquires its Durham spin-out bizjournals.com - June 8 at 4:49 PM
	Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine finance.yahoo.com - May 18 at 8:06 PM
	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TESS, STSA, CHRA marketwatch.com - May 3 at 5:56 PM
	Shareholder Alert: Ademi LLP investigates whether Satsuma Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Shin Nippon benzinga.com - May 1 at 8:34 AM
	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NATI, RXDX, STSA, CHRA marketwatch.com - April 25 at 4:05 PM
	STSA Satsuma Pharmaceuticals, Inc. seekingalpha.com - April 22 at 6:34 PM
	Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting finance.yahoo.com - April 21 at 10:22 AM
	After Satsuma Pharma Rockets 65% on SNBL Bid, There Could Still Be 6X More Upside msn.com - April 19 at 12:39 AM
	Satsuma Pharmaceuticals Shares Soar on Shin Nippon Biomedical Deal >STSA marketwatch.com - April 18 at 1:38 AM
	SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Satsuma Pharmaceuticals, Inc. Buyout benzinga.com - April 17 at 3:37 PM
	Peninsula company bets big part of potential $221M sale on future of migraine drug bizjournals.com - April 17 at 3:37 PM
	STSA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Satsuma Pharmaceuticals, Inc. Is Fair to Shareholders markets.buffalonews.com - April 17 at 10:36 AM
	Satsuma Pharma Agrees To Be Acquired By Shin Nippon Biomedical markets.businessinsider.com - April 17 at 10:36 AM
	Satsuma Skyrockets after Acquisition by Shin Nippon msn.com - April 17 at 10:36 AM
	Why Is Satsuma Pharmaceuticals (STSA) Stock Up 144% Today? investorplace.com - April 17 at 9:09 AM
	SNBL to Acquire Satsuma Pharmaceuticals finance.yahoo.com - April 16 at 11:18 PM
	H.C. Wainwright Reaffirms Their Buy Rating on Satsuma Pharmaceuticals (STSA) markets.businessinsider.com - March 30 at 10:15 AM
	We're A Little Worried About Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Rate finance.yahoo.com - March 30 at 10:15 AM
	Migraine drug maker seeks FDA approval and a partner as it cuts jobs bizjournals.com - March 29 at 1:49 PM
	Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights finance.yahoo.com - March 28 at 6:05 PM
	8-K: Satsuma Pharmaceuticals, Inc. marketwatch.com - February 18 at 2:42 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CTI BioPharma

NASDAQ:CTIC

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

DiaMedica Therapeutics

NASDAQ:DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Marker Therapeutics

NASDAQ:MRKR

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leukemia; and MT-601 which is in phase 1 clinical trial for the treatment of lymphoma, as well as in phase 1/2 clinical trial for the treatment of pancreatic cancer. Marker Therapeutics is headquartered in Houston, Texas.

Satsuma Pharmaceuticals

NASDAQ:STSA

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial